GlassScriptPhysician profile
Amanda Bock Blair
NPI 1215155197
$60,390.41
in general payments reported to CMS, 2019-2025
11 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,842 · 2021: $10K · 2022: $165 · 2023: $6,000 · 2024: $13K · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $1,338 · Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,143.25 |
| Travel and Lodging | $1,338.35 |
| Food and Beverage | $475.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $11,741.79 | 2019-2021 | |
| Genzyme Corporation | $11,683.78 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11,530.26 | 2020-2021 | |
| Shire North American Group INC | $10,318.07 | 2019 | |
| Novo Nordisk INC | $6,678.35 | 2019-2020 | |
| Hema Biologics, LLC | $6,000.00 | 2023 | Sevenfact |
| Bayer Healthcare Pharmaceuticals INC. | $2,406.14 | 2024-2025 | |
| Spark Therapeutics, INC. | $32.02 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.